Diacylglycerol kinase regulatory compound

Abstract

The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B. The compounds can be used alone or in combination with other drugs. TIFF2023509881001359.tif33128

Claims

1. A compound of formula (I), 【Chemical 1】 or a pharmaceutically acceptable salt thereof, wherein R １ is hydrogen, C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, C １～６ alkoxy, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, or -CN, and R ２ is hydrogen, C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxy, C ２～６ alkoxyalkyl, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, -CN, -NO, -NO ２ , -C(O)R ２ａ , -C(O)OR ２ａ , -OC(O)R ２ａ , -C(O)N(R ２ａ )(R ２ｂ ), -N(R ２ａ )(C(O)R ２ｂ , -OC(O)N(R ２ａ )(R ２ｂ ), -N(R ２ａ )(C(O)OR ２ｂ , -C(=NR ２ａ )(N(R ２ｂ )(R ２ｃ ), -N(R ２ａ )(R ２ｂ ), -N(R ２ａ )(N(R ２ｂ )(R ２ｃ ), -N(R ２ａ )(N=C(R ２ｂ )(OR ２ｃ ), -OR ２ａ , -SR ２ａ , -S(O)R ２ａ , -S(O)(NR ２ａ )(R ２ｂ ), -S(NR ２ａ )(NR ２ｂ )(R ２ｃ ), -S(O ２ R ２ａ , -S(O ２ (NR ２ａ )(R ２ｂ ), -N(R ２ａ )(S(O ２ (R ２ｂ ), -P(R ２ａ (R ２ｂ ), -P(O)(R ２ａ (R ２ｂ ), -P(O)(OR ２ａ )(R ２ｂ ), -P(O)(OR ２ａ )(OR ２ｂ ), C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１２ aryl, C １～６ alkyl-C ６～１２ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl), wherein each alkyl, alkenyl or alkynyl is independently optionally substituted with 1 to 3 R ２ｄ groups, each cycloalkyl is optionally substituted with 1 to 3 R ２ｅ groups, each aryl is optionally substituted with 1 to 3 R ２ｆ groups, each heterocycloalkyl is optionally substituted with 1 to 3 R ２ｇ groups, each heteroaryl is optionally substituted with 1 to 3 R ２ｈ groups, Each R ２ａ 、R ２ｂ 、and R ２ｃ are, independently, hydrogen, C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C ２～６ alkoxyalkyl, C １～６ haloalkyl, C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１２ aryl, C １～６ alkyl-C ６～１２ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl), where the aryl or heteroaryl is optionally substituted with 1 to 3 R ２ｊ s, Alternatively, R ２ａ , R ２ｂ , and R ２ｃ may, when attached to the same atom, combine with the atom to which they are attached to form a heterocycloalkyl. Each R ２ｄ is, independently, -CN, -C(O)R ２ｄ１ -C(O)OR ２ｄ１ -OC(O)R ２ｄ１ -C(O)N(R ２ｄ１ )(R ２ｄ２ -N(R ２ｄ１ )(R ２ｄ２ -OC(O)N(R ２ｄ１ )(R ２ｄ２ -N(R ２ｄ１ )(R ２ｄ２ -N(R ２ｄ１ )(R ２ｄ２ =O, -OR ２ｄ１ -SR ２ｄ１ -S(O)R ２ｄ１ -S(O)(NR ２ｄ１ )(R ２ｄ２ -S(O) ２ R ２ｄ１ -S(O)N(R ２ｄ１ )(R ２ｄ２ -N(R ２ｄ１ )(R ２ R ２ｄ２ C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１２ aryl, C １～６ alkyl-C ６～１２ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl), and Each R ２ｄ１ and R ２ｄ２ is, independently, hydrogen, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C ２～６ alkoxyalkyl, or C １～６ haloalkyl, and Each R ２ｅ 、R ２ｆ 、R ２ｇ 、and R ２ｈ is, independently, hydrogen, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxy, C ２～６ alkoxyalkyl, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, -CN, or -OH, and Each R ２ｊ is independently C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxy, C ２～６ alkoxyalkyl, halogen, C １～６ haloalkyl, or C １～６ haloalkoxy, and R ３ is hydrogen, C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxy, C ２～６ alkoxyalkyl, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, -CN, -NO, -NO ２ , -C(O)R ３ａ , -C(O)OR ３ａ , -OC(O)R ３ａ , -C(O)N(R ３ａ )(R ３ｂ ), -N(R ３ａ )(C(O)R ３ｂ , -OC(O)N(R ３ａ )(R ３ｂ ), -N(R ３ａ )(C(O)OR ３ｂ , -C(=NR ３ａ )(N(R ３ｂ )(R ３ｃ ), -N(R ３ａ )(R ３ｂ ), -N(R ３ａ )(N(R ３ｂ )(R ３ｃ ), -N(R ３ａ )(N=C(R ３ｂ )(OR ３ｃ ), -OR ３ａ , -SR ３ａ , -S(O)R ３ａ , -S(O)(NR ３ａ )(R ３ｂ ), -S(NR ３ａ )(NR ３ｂ )(R ３ｃ ), -S(O ２ R ３ａ ), -S(O ２ (NR ３ａ )(R ３ｂ ), -N(R ３ａ )(S(O ２ (R ３ｂ ), -P(R ３ａ (R ３ｂ ), -P(O)(R ３ａ (R ３ｂ ), -P(O)(OR ３ａ )(R ３ｂ ), -P(O)(OR ３ａ )(OR ３ｂ ), C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１２ aryl, C １～６ alkyl-C ６～１２ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl), wherein each alkenyl or alkynyl is independently optionally substituted with 1 to 3 R ３ｄ groups, each cycloalkyl is optionally substituted with 1 to 3 R ３ｅ groups, each aryl is optionally substituted with 1 to 3 R ３ｆ groups, each heterocycloalkyl is optionally substituted with 1 to 3 R ３ｇ groups, each heteroaryl is optionally substituted with 1 to 3 R ３ｈ groups, and Each R ３ａ , R ３ｂ , and R ３ｃ is independently hydrogen, C １～６ alkyl, C １～６ hydroxyalkyl, C ２～６ alkoxyalkyl, C １～６ haloalkyl, C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１２ aryl, C １～６ alkyl-C ６～１２ aryl, heterocycloalkyl, or heteroaryl, and Alternatively, R ３ａ , R ３ｂ , and R ３ｃ when attached to the same atom, can combine with the atom to which they are attached to form a heterocycloalkyl. Each R ３ｄ is independently, -N(R ３ｄ１ )(R ３ｄ２ ), -OR ３ｄ１ , C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１２ aryl, C １～６ alkyl-C ６～１２ aryl, heterocycloalkyl, or heteroaryl, and Each R ３ｄ１ and R ３ｄ２ are, independently, hydrogen, C １～６ alkyl, or -C(O)O-(C １～６ alkyl), and Each R ３ｅ 、R ３ｆ 、R ３ｇ 、and R ３ｈ is, independently, hydrogen, C １～６ alkyl, C １～６ alkoxy, halogen, C １～６ haloalkyl, or C １～６ haloalkoxy, R ４ is hydrogen, C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, C １～６ alkoxy, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, or -CN, and R ５ is C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, C １～６ hydroxyalkyl, C ２～６ alkoxyalkyl, C １～６ haloalkyl, C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１２ aryl, C １～６ alkyl-C ６～１２ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl), and R ６ is aryl or heteroaryl, and these aryl or heteroaryl are each optionally substituted with 1 to 3 R ６～１２ groups, ６ａ and each is optionally substituted. Each R ６ａ is independently C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxy, C ２～６ alkoxyalkyl, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, -CN, -NO ２ , -C(O)R ６ｂ , -C(O)OR ６ｂ , -OC(O)R ６ｂ , -C(O)N(R ６ｂ )(R ６ｃ ), -N(R ６ｂ )(R ６ｃ ), -C(=NR ６ｂ )(N(R ６ｃ )(R ６ｄ ), -N(R ６ｂ )(R ６ｃ ), -OR ６ｂ , -SR ６ｂ , -S(O)R ６ｂ , -S(O) ２ R ６ｂ , -S(NR ６ｂ )(NR ６ｃ )R ６ｄ , -S(O)(NR ６ｂ )(R ６ｃ ), -S(O) ２ N(R ６ｂ )(R ６ｃ ), -N(R ６ｂ )(S(O) ２ (R ６ｃ ), -P(R ６ｂ )(R ６ｃ ), -P(O)(R ６ｂ )(R ６ｃ ), -P(O)(OR ６ｂ )(R ６ｃ ), -P(O)(OR ６ｂ )(OR ６ｃ ), C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１２ aryl, C １～６ Alkyl-C ６～１２ Aryl, heterocycloalkyl, C １～６ Alkyl-(heterocycloalkyl), heteroaryl, or C １～６ Alkyl-(heteroaryl), wherein cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is each optionally substituted with 1 to 3 R ６ｅ and alkyl is optionally substituted with R ６ｆ and alkynyl is optionally substituted with 1 to 4 R ６ｊ and Each R ６ｂ , R ６ｃ and R ６ｄ are, independently, hydrogen, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C ２～６ alkoxyalkyl, C １～６ haloalkyl, C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１２ aryl, C １～６ alkyl-C ６～１２ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl), where cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted by 1 to 3 R ６ｋ ; Each R ６ｋ is, independently, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxy, C ２～６ alkoxyalkyl, C １～６ haloalkyl, C １～６ haloalkoxy, C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, heterocycloalkyl, or C １～６ alkyl-(heterocycloalkyl), and Each R ６ｅ is independently C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxy, C ２～６ alkoxyalkyl, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, -CN, -NO ２ , -C(O)R ６ｅ１ , -C(O)OR ６ｅ１ , -OC(O)R ６ｅ１ , -C(O)N(R ６ｅ１ )(R ６ｅ２ ), -N(R ６ｅ１ )C(O)R ６ｅ２ , -OC(O)N(R ６ｅ１ )(R ６ｅ２ ), -N(R ６ｅ１ )C(O)OR ６ｅ２ , -C(=NR ６ｅ１ )N(R ６ｅ２ )(R ６ｅ３ ), -N(R ６ｅ１ )(R ６ｅ２ ), =O, -OR ６ｅ１ , -SR ６ｅ１ , -S(O)R ６ｅ１ , -S(NR ６ｅ１ )(NR ６ｅ２ ), -S(O)(NR ６ｅ１ )(R ６ｅ２ ), -S(O) ２ R ６ｅ１ , -S(O) ２ N(R ６ｅ１ )(R ６ｅ２ ), -SF ５ , -N(R ６ｅ１ )S(O) ２ (R ６ｅ２ ), -P(R ６ｅ１ )(R ６ｅ２ ), -P(O)(R ６ｅ１ )(R ６ｅ２ ), -P(O)(OR ６ｅ１ )(R ６ｅ２ ), -P(O)(OR ６ｅ１ )(OR ６ｅ２ ), -Si(R ６ｅ１ )(R ６ｅ２ )(R ６ｅ３ ), C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１２ aryl, C １～６ alkyl-C ６～１２ aryl, heterocycloalkyl, C １～６ alkyl-heterocycloalkyl, heteroaryl, or C １～６ alkyl-heteroaryl, wherein cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is each optionally substituted with 1 to 3 R ６ｈ and alkyl is optionally substituted with 1 to 3 R ６ｍ and Each R ６ｅ１ 、R ６ｅ２ 、and R ６ｅ３ is independently hydrogen, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxyalkyl, C １～６ haloalkyl, C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１０ aryl, C １～６ alkyl-C ６～１０ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl), where cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with 1 to 3 R ６ｎ s, Each R ６ｎ is C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxy, C ２～６ alkoxyalkyl, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, -CN, -C(O)R ６ｎ１ , -C(O)OR ６ｎ１ , -OC(O)R ６ｎ１ , -C(O)N(R ６ｎ１ )(R ６ｎ２ ), -N(R ６ｎ１ )(R ６ｎ２ ), -OC(O)N(R ６ｎ１ )(R ６ｎ２ ), -N(R ６ｎ１ )(C(O)OR ６ｎ２ , -C(=NR ６ｎ１ )(N(R ６ｎ２ )(R ６ｎ３ ), -N(R ６ｎ１ )(R ６ｎ２ ), =O, -OH, -SR ６ｎ１ , -S(O)R ６ｎ１ , -S(NR ６ｎ１ )(NR ６ｎ２ )(R ６ｎ３ , -S(O)(NR ６ｎ１ )(R ６ｎ２ ), -S(O) ２ R ６ｎ１ , -S(O) ２ N(R ６ｎ１ )(R ６ｎ２ ), or -N(R ６ｎ１ )(S(O) ２ (R ６ｎ２ ) and Each R ６ｎ１ 、R ６ｎ２ and R ６ｎ３ is, independently, hydrogen, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C ２～６ alkoxyalkyl, C １～６ haloalkyl, C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１０ aryl, C １～６ alkyl-C ６～１０ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl), and Each R ６ｈ is independently C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxy, C ２～６ alkoxyalkyl, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, -CN, -C(O)R ６ｈ１ , -C(O)OR ６ｈ１ , -OC(O)R ６ｈ１ , -C(O)N(R ６ｈ１ )(R ６ｈ２ ), -N(R ６ｈ１ )(R ６ｈ２ ), -OC(O)N(R ６ｈ１ )(R ６ｈ２ ), -N(R ６ｈ１ )(C(O)OR ６ｈ２ , -C(=NR ６ｈ１ )(N(R ６ｈ２ )(R ６ｈ３ ), -N(R ６ｈ１ )(R ６ｈ２ ), =O, -OH, -SR ６ｈ１ , -S(O)R ６ｈ１ , -S(NR ６ｈ１ )(NR ６ｈ２ )(R ６ｈ３ , -S(O)(NR ６ｈ１ )(R ６ｈ２ ), -S(O) ２ R ６ｈ１ , -S(O) ２ N(R ６ｈ１ )(R ６ｈ２ ), -N(R ６ｈ１ )(S(O) ２ (R ６ｈ２ ), C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, heterocycloalkyl, or C １～６ alkyl-(heterocycloalkyl), Each R ６ｈ１ 、R ６ｈ２ 、and R ６ｈ３ are, independently, hydrogen, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C ２～６ alkoxyalkyl, C １～６ haloalkyl, C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１０ aryl, C １～６ alkyl-C ６～１０ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl), and Each R ６ｍ is, independently, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, -CN, -C(O)R ６ｍ１ , -C(O)OR ６ｍ１ , -OC(O)R ６ｍ１ , -C(O)N(R ６ｍ１ )(R ６ｍ２ ), -N(R ６ｍ３ )(R ６ｍ２ ), -OC(O)N(R ６ｍ１ )(R ６ｍ２ ), -N(R ６ｍ１ )(R ６ｍ２ ), -C(=NR ６ｍ３ )(R ６ｍ１ )(R ６ｍ２ ), -N(R ６ｍ１ )(R ６ｍ２ ), =O, -OH, -SR ６ｍ１ , -S(O)R ６ｍ１ , -S(NR ６ｍ１ )(NR ６ｍ２ )(R ６ｍ３ ), -S(O)(NR ６ｍ１ )(R ６ｍ２ ), -S(O) ２ R ６ｍ１ ), -S(O) ２ N(R ６ｍ１ )(R ６ｍ２ ), or -N(R ６ｍ３ )(R ２ )(R ６ｍ２ ), and Each R ６ｍ１ , R ６ｍ２ , and R ６ｍ３ is, independently, hydrogen, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C ２～６ alkoxyalkyl, C １～６ haloalkyl, C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１０ aryl, C １～６ alkyl-C ６～１０ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl). R ６ｆ is -OSi(R ６ｆ１ )(R ６ｆ２ )(R ６ｆ３ ) and R ６ｆ１ 、 R ６ｆ２ 、 and R ６ｆ３ are each independently C １～６ alkyl, Each R ６ｊ is, independently, C ２～６ alkoxyalkyl, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, -CN, -C(O)R ６ｊ１ , -C(O)OR ６ｊ１ , -OC(O)R ６ｊ１ , -C(O)N(R ６ｊ１ )(R ６ｊ２ ), -N(R ６ｊ３ )C(O)R ６ｊ２ , -OC(O)N(R ６ｊ１ )(R ６ｊ２ ), -N(R ６ｊ１ )C(O)OR ６ｊ２ , -C(=NR ６ｊ３ )N(R ６ｊ１ )(R ６ｊ２ ), -N(R ６ｊ１ )(R ６ｊ２ ), =O, -OR ６ｊ１ , -SR ６ｊ１ , -S(O)R ６ｊ１ , -S(NR ６ｊ１ )(NR ６ｊ２ ), -S(NR ６ｊ１ )(NR ６ｊ２ )R ６ｊ３ , -S(O)(NR ６ｊ１ )(R ６ｊ２ ), -S(O) ２ R ６ｊ１ , -S(O) ２ N(R ６ｊ１ )(R ６ｊ２ ), -N(R ６ｊ１ )S(O) ２ (R ６ｊ２ ), -Si(R ６ｊ１ )(R ６ｊ２ )(R ６ｊ３ ), C ３～１０ cycloalkyl, C ６～１２ aryl, heterocycloalkyl, or heteroaryl, where the cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted with 1 to 3 R ６ｐ s, Each R ６ｊ１ 、R ６ｊ２ 、and R ６ｊ３ is, independently, hydrogen, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C ２～６ alkoxyalkyl, C １～６ haloalkyl, C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１０ aryl, C １～６ alkyl-C ６～１０ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl), and Each R ６ｐ is, independently, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxy, C ２～６ alkoxyalkyl, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, -CN, -C(O)R ６ｐ１ , -C(O)OR ６ｐ１ , -OC(O)R ６ｐ１ , -C(O)N(R ６ｐ１ )(R ６ｐ２ ), -N(R ６ｐ１ )(R ６ｐ２ ), -OC(O)N(R ６ｐ１ )(R ６ｐ２ ), -N(R ６ｐ１ )(R ６ｐ２ ), -C(=NR ６ｐ３ )(R ６ｐ１ )(R ６ｐ２ ), -N(R ６ｐ１ )(R ６ｐ２ ), =O, -OH, -SR ６ｐ１ , -S(O)R ６ｐ１ , -S(NR ６ｐ１ )(NR ６ｐ２ )(R ６ｐ３ , -S(O)(NR ６ｐ１ )(R ６ｐ２ ), -S(O) ２ R ６ｐ１ , -S(O) ２ N(R ６ｐ１ )(R ６ｐ２ ), or -N(R ６ｐ１ )(R ２ )(R ６ｐ２ ) and Each R ６ｐ１ , R ６ｐ２ , and R ６ｐ３ is, independently, hydrogen, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C ２～６ alkoxyalkyl, C １～６ haloalkyl, C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, C ６～１０ aryl, C １～６ alkyl-C ６～１０ aryl, heterocycloalkyl, C １～６ alkyl-(heterocycloalkyl), heteroaryl, or C １～６ alkyl-(heteroaryl). Or, R ５ and one R ６ａ together with the atom to which they are attached form a heterocycloalkyl, which is optionally substituted with 1 to 3 R ６ｇ groups, Each R ６ｇ is independently C １～６ alkyl, C ２～６ alkenyl, C ２～６ alkynyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C ２～６ alkoxyalkyl, halogen, C １～６ haloalkyl, C １～６ haloalkoxy, or -CN, and R ７ is hydrogen, C １～６ alkyl, C １～６ hydroxyalkyl, C １～６ aminoalkyl, C １～６ alkoxy, C ２～６ alkoxyalkyl, C １～６ alkylthio, halogen, C １～６ haloalkyl, -CN, -OH, -NH ２ , C ３～１０ cycloalkyl, C １～６ alkyl-C ３～１０ cycloalkyl, heterocycloalkyl, or C １～６ alkyl-(heterocycloalkyl), and each heterocycloalkyl is a 3- to 20-membered ring having 1 to 4 heteroatoms each independently being N, O, or S, each heteroaryl is a 5- to 18-membered ring having 1 to 4 heteroatoms each independently being N, O, or S, the compound or a pharmaceutically acceptable salt thereof.

2. In the formula, R １ is hydrogen, C １～３ alkyl, C １～３ alkoxy, or halogen, and the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

3. wherein R ２ is hydrogen, C １～３ alkyl, C ２～３ alkenyl, C ２～６ alkynyl, C １～３ hydroxyalkyl, C １～３ alkoxy, C ２～３ alkoxyalkyl, halogen, C １～３ haloalkyl, -CN, -NO, -NO ２ , -C(O)R ２ａ , -C(O)OR ２ａ , -N(R ２ａ )(C(O)R ２ｂ ), -N(R ２ａ )(R ２ｂ ), -N(R ２ａ )(S(O) ２ )(R ２ｂ ), C ３～６ cycloalkyl, phenyl, a 5- to 6-membered heterocycloalkyl ring having 1 to 2 heteroatoms each independently being N or O, or a 5- to 6-membered heteroaryl ring having 1 to 2 heteroatoms each independently being N, O, or S, wherein each alkenyl or alkynyl is independently optionally substituted with one R ２ｄ group, and each phenyl is optionally substituted with one R ２ｆ group, Each R ２ａ and R ２ｂ is, independently, hydrogen, C １～３ alkyl, C １～３ hydroxyalkyl, or C ２～３ alkoxyalkyl, Each R ２ｄ is independently, -N(R ２ｄ１ )(R ２ｄ２ ), -OR ２ｄ１ , C ３～８ cycloalkyl, or phenyl, and Each R ２ｄ１ and R ２ｄ２ is, independently, hydrogen or -C(O)O-(C １～４ alkyl), Each R ２ｆ is, independently, C １～３ alkoxy or halogen, a compound according to claim 1 or 2 or a pharmaceutically acceptable salt thereof.

4. wherein R ３ is hydrogen, Me, Et, -CH ２ OH, -OMe, -CH ２ OMe, F, Cl, Br, -CN, -NO ２ , -COOMe, -CONH ２ , -NH ２ , -NHSO ２ Me, or, 【Chemical 2】 The compound or a pharmaceutically acceptable salt thereof according to any one of Claims 1 to 3, wherein is

5. In the formula, R ４ is hydrogen, C １～６ alkyl, or halogen, and the compound according to any one of claims 1 to 4 or a pharmaceutically acceptable salt thereof.

6. wherein Each R ６ａ is, independently, [Chemical Formula 3] 【Chemical Formula 4】 【Chemical Formula 5】 【Chemical Formula 6】 【Chemical Formula 7】 The compound or a pharmaceutically acceptable salt thereof according to any one of Claims 1 to 5, wherein is

7. having the structure of formula (IIc), [Chemical 8] wherein Ring A is a 5- to 8-membered heterocycloalkyl optionally having 1 to 2 additional heteroatoms each independently being N, O, or S, and optionally, in the formula, Ring A is substituted with 1 or 2 R ６ｇ and is substituted with n is 0, 1, or 2, The compound or a pharmaceutically acceptable salt thereof according to any one of Claims 1 to 6.

8. wherein 【Chemical Formula 9】 is 【Chemical Formula 10】 The compound or a pharmaceutically acceptable salt thereof according to Claim 7, having the structure of

9. wherein 【Chemical 11】 is 【Chemical Formula 12】 【Chemical 13】 The compound or a pharmaceutically acceptable salt thereof according to Claim 7, having the structure of

10. wherein R １ The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof, wherein R is hydrogen or halogen.

11. wherein R ４ is hydrogen, C １～３ alkyl, or halogen, and is a compound according to any one of claims 1 to 10 or a pharmaceutically acceptable salt thereof.

12. In the formula, R ２ is hydrogen, halogen, or -CN, and is the compound according to any one of claims 1 to 11 or a pharmaceutically acceptable salt thereof.

13. In the formula, R ３ is hydrogen, F, or Cl, and the compound according to any one of claims 1 to 12 or a pharmaceutically acceptable salt thereof.

14. Table 1A , Table 1B , Table 1C , Table 1D , Table 1E , Table 1F , Table 1G , Table 1H , Table 1I , Table 1J , Table 2A , Table 2B , Table 2C , Table 2D , Table 2E , Table 2F , Table 2G , Table 2H , Table 2I , Table 2J , Table 2K , Table 2L , Table 3A , Table 3B , Table 3C , Table 3D , Table 3E , Table 3F , Table 3G , Table 3H , Table 3I , Table 3J , or Table 3K The compound or a pharmaceutically acceptable salt thereof having the structure of the compound in.

15. The compound or a pharmaceutically acceptable salt thereof having the following structure. 【Chemical Formula 14】

16. The compound or a pharmaceutically acceptable salt thereof having the following structure. 【Chemical Formula 15】

17. The compound or a pharmaceutically acceptable salt thereof having the following structure. 【Chemical Formula 16】

18. The compound or a pharmaceutically acceptable salt thereof having the following structure. 【Chemical 17】

19. The compound or a pharmaceutically acceptable salt thereof having the following structure. 【Chemical Formula 18】

20. The compound or a pharmaceutically acceptable salt thereof having the following structure. 【Chemical Formula 19】

21. A pharmaceutical composition comprising a pharmaceutically effective amount of the compound or a pharmaceutically acceptable salt thereof according to any one of Claims 1 to 20 and a pharmaceutically acceptable carrier or excipient.

Images